Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II open-label study of JWCAR029 in relapsed/refractory B-cell non-Hodgkin lymphoma
CTR20182325Phase 2Active
- Sponsor
- Shanghai Mingju Biotechnology
- Start
- Jul 2019
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of relmacabtagene autoleucel in mature B-cell lymphoma, follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), large-cell lymphoma, primary mediastinal large B-cell lymphoma (PMBCL), sponsored by Shanghai Mingju Biotechnology. Started Jul 2019; status: active.
02
Drugs
relmacabtagene autoleucel
03
Conditions
mature B-cell lymphomafollicular lymphoma (FL)diffuse large B-cell lymphoma (DLBCL)large-cell lymphomaprimary mediastinal large B-cell lymphoma (PMBCL)
Beyond the preview
Go deeper on CTR20182325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20182325.